CLINICAL AND PROPHYLACTIC DETERMINANTS OF COMORBID DISEASES IN METABOLIC SYNDROME
Keywords:
Metabolic syndrome, comorbidities, insulin resistance, obesity, cardiovascular diseases, prevention, lifestyle modificationsAbstract
Metabolic syndrome (MetS) is a cluster of interrelated metabolic abnormalities, including obesity, hypertension, dyslipidemia, and insulin resistance, which significantly increase the risk of cardiovascular diseases, type 2 diabetes, and other comorbid conditions. This article explores the clinical and prophylactic determinants of comorbid diseases in MetS, emphasizing the importance of early diagnosis, lifestyle modifications, and targeted therapeutic interventions. The interplay of genetic, environmental, and behavioral factors contributes to the development and progression of MetS and its associated comorbidities. Effective management strategies, including dietary changes, physical activity, pharmacological treatments, and patient education, are critical in reducing the burden of MetS and improving patient outcomes. This article highlights the need for a multidisciplinary approach to address the complex nature of MetS and its comorbidities, aiming to enhance preventive and therapeutic measures.
References
[1] Alberti, K. G., Eckel, R. H., Grundy, S. M., et al. (2009). Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention. Circulation, 120(16), 1640-1645.
[2] Grundy, S. M. (2016). Metabolic syndrome update. Trends in Cardiovascular Medicine, 26(4), 364-373.
[3] Samson, S. L., & Garber, A. J. (2014). Metabolic syndrome. Endocrinology and Metabolism Clinics of North America, 43(1), 1-23.
[4] Saklayen, M. G. (2018). The global epidemic of the metabolic syndrome. Current Hypertension Reports, 20(2), 12.
[5] Kaur, J. (2014). A comprehensive review on metabolic syndrome. Cardiology Research and Practice, 2014, 943162.
[6] Reaven, G. M. (2011). Insulin resistance: The link between obesity and cardiovascular disease. Medical Clinics of North America, 95(5), 875-892.
[7] Després, J. P., & Lemieux, I. (2006). Abdominal obesity and metabolic syndrome. Nature, 444(7121), 881-887.
[8] Lastra, G., Dhuper, S., Johnson, M. S., & Sowers, J. R. (2010). Salt, aldosterone, and insulin resistance: Impact on the cardiovascular system. Nature Reviews Cardiology, 7(10), 577-584.
[9] Ginsberg, H. N., & MacCallum, P. R. (2009). The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: Part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus. Journal of the Cardiometabolic Syndrome, 4(2), 113-119.
[10] Esposito, K., Maiorino, M. I., Bellastella, G., et al. (2015). A journey into a Mediterranean diet and type 2 diabetes: A systematic review with meta-analyses. BMJ Open, 5(8), e008222.
[11] Strasser, B., & Schobersberger, W. (2011). Evidence for resistance training as a treatment therapy in obesity. Journal of Obesity, 2011, 482564.
[12] Garber, A. J., Abrahamson, M. J., Barzilay, J. I., et al. (2019). Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm. Endocrine Practice, 25(1), 69-100.
[13] Wadden, T. A., Webb, V. L., Moran, C. H., & Bailer, B. A. (2012). Lifestyle modification for obesity: New developments in diet, physical activity, and behavior therapy. Circulation, 125(9), 1157-1170.
[14] Younk, L. M., Davis, S. N., & Davis, S. N. (2011). Multidisciplinary approach to the management of the metabolic syndrome. Current Diabetes Reports, 11(1), 61-69.
[15] Esposito, K., Maiorino, M. I., Bellastella, G., et al. (2015). A journey into a Mediterranean diet and type 2 diabetes: A systematic review with meta-analyses. BMJ Open, 5(8), e008222.
[16] Strasser, B., & Schobersberger, W. (2011). Evidence for resistance training as a treatment therapy in obesity. Journal of Obesity, 2011, 482564.
[17] Garber, A. J., Abrahamson, M. J., Barzilay, J. I., et al. (2019). Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm. Endocrine Practice, 25(1), 69-100.
[18] Wadden, T. A., Webb, V. L., Moran, C. H., & Bailer, B. A. (2012). Lifestyle modification for obesity: New developments in diet, physical activity, and behavior therapy. Circulation, 125(9), 1157-1170.
[19] Younk, L. M., Davis, S. N., & Davis, S. N. (2011). Multidisciplinary approach to the management of the metabolic syndrome. Current Diabetes Reports, 11(1), 61-69.
[20] Reaven, G. M. (2011). Insulin resistance: The link between obesity and cardiovascular disease. Medical Clinics of North America, 95(5), 875-892.
Published
Issue
Section
License
Copyright (c) 2024 M.S. Masharipova, U.K. Kаyumov, G.S. Xalimbetov (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
All Rights Reserved.
